A Case Comprehensive Cancer-led team has received $10.4 million over five years from NCI to explore at the molecular level the differences in glioblastoma between males and females.
The New York Proton Center established a comprehensive Proton Therapy School aimed at educating clinicians on utilization and optimally delivery of modern pencil beam-scanning proton therapy.
Moffitt Cancer Center is launching a nationwide study to help educate oncologists and address health care disparities among LGBTQ+ patients.
NCI's cancer screening trials may be falling victim to the COVID-19 pandemic.
Gavreto (pralsetinib) has received an accelerated approval from FDA for adult patients with metastatic RET fusion-positive non-small cell lung cancer, as detected by an FDA-approved test.
The Oncomine Dx Target Test as a companion diagnostic has received FDA approval to identify RET fusion-positive, metastatic non-small cell lung cancer patients who are candidates for Gavreto (pralsetinib), a targeted therapy developed by Blueprint Medicines.
FDA has alerted health care professionals, oncology clinical investigators, and patients that a clinical trial studying the use of atezolizumab (Tecentriq) and paclitaxel in patients with previously untreated inoperable locally advanced or metastatic triple negative breast cancer showed the drug combination did not work to treat the disease.
DetermaRx has received a pricing decision from Centers for Medicare and Medicaid Services.
MD Anderson Cancer Center and Xencor Inc. are working together on investigational treatments for patients with a variety of cancer types. The parties will collaborate to design and execute additional clinical studies with Xencor's portfolio of XmAb drug candidates, including novel bispecific antibodies and engineered cytokines. Xencor is committing to funding and supporting these studies over an initial five-year term.
